Bio-Convert Receives Encouraging Feedback from DKMA
Bio-Convert A/S is thrilled to share that it has recently received positive and constructive feedback from the Danish Medicine Agency (DKMA). This feedback pertains to its lead drug candidate QR-02, specifically designed for the treatment of oral leukoplakia.
This endorsement from DKMA opens the door for a pivotal First in Human trial, indicating a high probability that animal studies may no longer be necessary for the proposed drug formulation and its intended route of application.
Allan Wehnert, the CEO and Founder of Bio-Convert, expressed his enthusiasm regarding this development. He stated, "The guidance provided by DKMA has been invaluable, as it clearly paves the way for commencing our First in Human trial with QR-02, which we anticipate will begin at the end of this year."
What sets QR-02 apart is Bio-Convert's innovative and proprietary mucoadhesive oral topical formulation that specifically targets oral leukoplakia with moderate to severe dysplasia. This unique gel formulation has a remarkable ability to adhere to the oral cavity for an extended duration of 12 to 24 hours. In contrast, conventional gel formulations typically wash away in just 15 to 20 minutes due to saliva.
The active ingredient in QR-02, imiquimod, is already approved for treating conditions such as Actinic Keratosis, External Genital Warts, and Superficial Basal Cell Carcinoma (sBCC). By focusing on the treatment of oral leukoplakia, Bio-Convert aims to potentially cure and alleviate the dysplasia levels in affected patients, providing a much-needed breakthrough in the management of this condition.
Innovative Drug Delivery Technology
Bio-Convert is committed to revolutionizing the treatment of oral leukoplakia. The company's mission emphasizes a focus on developing an effective treatment for this condition, which is often overlooked in the current therapeutic landscape.
The proprietary delivery technology behind QR-02 ensures more precise, effective, and efficient treatment outcomes. This innovation not only aims to improve patient care but also to stand as a transformative option in the realm of oral medicine.
Expanding Horizons in Life Sciences
Nordicus Partners Corporation (OTCQB: NORD), the parent company of Bio-Convert, plays a vital role in supporting Nordic and U.S. life sciences companies in their journey toward establishing a presence in the U.S. market. With a wealth of experience in corporate finance and strategic market development, Nordicus has a proven track record in nurturing the growth of biotechnology firms.
In 2024, Nordicus made significant strides by acquiring 100% of Orocidin A/S, a Danish preclinical-stage biotech company focused on developing next-generation therapies for periodontitis, along with Bio-Convert A/S. This consolidation of expertise and resources reflects their commitment to advancing innovative solutions in the life sciences sector.
Future Prospects
With the promising feedback from DKMA and the innovative edge of QR-02, Bio-Convert is poised for a significant milestone in its journey. The anticipated First in Human trial will not only pave the way for future developments but also enhance treatment options for patients suffering from oral leukoplakia.
For interested parties seeking more information about Bio-Convert or to engage with the company's leadership, they are encouraged to reach out to Mr. Henrik Rouf, Chief Executive Officer. He can be contacted at hr@nordicuspartners.com or by phone at +1 310 666 0750.
Frequently Asked Questions
What is QR-02?
QR-02 is a mucoadhesive oral topical formulation developed by Bio-Convert for the treatment of oral leukoplakia.
What feedback did Bio-Convert receive from DKMA?
DKMA provided positive feedback indicating a clear pathway for Bio-Convert to move forward with their First in Human trial.
What are the unique features of QR-02?
QR-02's gel formulation can adhere to the oral cavity for 12 to 24 hours, significantly longer than traditional formulations.
Who can I contact for more information about Bio-Convert?
For inquiries, you can reach out to Mr. Henrik Rouf, Chief Executive Officer, via email at hr@nordicuspartners.com or call +1 310 666 0750.
What role does Nordicus Partners Corporation play?
Nordicus is a financial consulting company that supports Nordic and U.S. life sciences firms in establishing themselves in the U.S. market.
